论文部分内容阅读
目的:探讨维生素B12联合依帕司他对糖尿病周围神经病患者血清超氧化物歧化酶(SOD)及丙二醛(MDA)水平的影响。方法:收集我院收治的98例2型糖尿病伴周围神经病变患者,随机分为实验组和对照组,每组49例。对照组患者给予依帕司他片50 mg/次,3次/d;实验组患者在对照组基础上给予维生素B12 25~100μg/次,1次/d治疗连续4周。观察并比较两组患者周围神经评分(TCSS评分)、血清SOD、MDA水平以及临床疗效。结果:与治疗前相比,两组患者的TCSS评分、MDA水平均下降血清SOD水平升高,差异具有统计学意义(P<0.05);与对照组相比,实验组患者的TCSS评分、丙二醛(MDA)水平较低,血清SOD水平较高差异具有统计学意义(P<0.05);与对照组相比,实验组患者的治疗总有效率较高,差异具有统计学意义(P<0.05);两组患者均未有明显的不良反应差异无统计学意义(P>0.05)。结论:维生素B12联合依帕司他能够改善糖尿病周围神经病患者血清MDA、SOD水平,对临床有指导意义。
Objective: To investigate the effect of vitamin B12 combined with epalrestat on serum superoxide dismutase (SOD) and malondialdehyde (MDA) in patients with diabetic peripheral neuropathy. Methods: 98 patients with type 2 diabetes mellitus and peripheral neuropathy admitted in our hospital were randomly divided into experimental group and control group, 49 cases in each group. Patients in the control group were treated with epalrestat 50 mg / time, 3 times / d. Patients in the experimental group were given vitamin B12 25-100 μg / time on the basis of the control group and once / d for 4 weeks. Peripheral nerve score (TCSS), serum SOD and MDA levels and clinical efficacy were observed and compared between two groups. Results: Compared with pretreatment, TCSS score and MDA level decreased in both groups, and the difference was statistically significant (P <0.05). Compared with the control group, the TCSS score, (P <0.05). Compared with the control group, the total effective rate of treatment group was higher, the difference was statistically significant (P < 0.05). There was no significant difference between the two groups in patients with significant adverse reactions (P> 0.05). Conclusion: Vitamin B12 combined with epalrestat can improve serum levels of MDA and SOD in patients with diabetic peripheral neuropathy, which is of clinical significance.